SCHEMBL2764398

SCHEMBL2764398

c1cc(C23CC4CC(CC(C4)C2)C3)n[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.39
KMT2A Q03164 6/20 0.39
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 3/20 0.39
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
GPR55 Q9Y2T6 1/20 0.38
TSHR P16473 1/20 0.37
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
MAPT P10636 2/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
GFER P55789 1/20 0.35
USP2 O75604 1/20 0.35
THRB P10828 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
RAB9A P51151 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9030942 0.81 GRIN2D (0.55) ALDH1A1LMNASMN1; SMN2TSHRPOLB
SCHEMBL31462470 0.77 GRIN1 (0.42) MEN1KMT2ALMNAPOLBNPSR1
SCHEMBL1239170 0.72 HSD11B1 (0.31)
SCHEMBL26132728 0.68 GRIN2D (0.33) MEN1KMT2ASMN1; SMN2USP2
SCHEMBL2357928 0.68 ALDH1A1 (0.38) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL10346681 0.67 TSHR (0.47) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL2765448 0.65 TSHR (0.42) MEN1KMT2AALDH1A1KDM4ESMN1; SMN2
SCHEMBL9030953 0.65 SMN1; SMN2 (0.42) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL9429608 0.64 EPHX2 (0.43) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL9726361 0.64 PDCD1 (0.50) MEN1KMT2AALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240245670-A1 DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES NOVARTIS AG (CH) 2024-07-25 US disclosed
EP-1266911-B1 Catalyst for addition polymerization and process for producing an addition polymer SUMITOMO CHEMICAL CO (JP) 2010-04-14 EP disclosed
CN-1302026-C Additional polymerization catalyst and its production process SUMITOMO CHEMICAL CO (JP) 2007-02-28 CN disclosed
US-6881802-B2 Catalyst for addition polymerization and process for producing an addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-04-19 US disclosed
US-20030032743-A1 Catalyst for addition polymerization and process for producing an addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-02-13 US disclosed
CN-1390864-A Additional polymerization catalyst and its production process SUMITOMO CHEMICAL CO (JP) 2003-01-15 CN disclosed
EP-1266911-A1 Catalyst for addition polymerization and process for producing an addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-12-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240245670-A1 DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES IKZF1, IKZF2, IKZF3 MEN1 2870/4885KMT2A 449/4885ALDH1A1 2942/4885
US-20030032743-A1 Catalyst for addition polymerization and process for producing an addition polymer BRAP, MCM4, BOLA2; BOLA2B MEN1 632/4885KMT2A 1204/4885ALDH1A1 3572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.